c. 1181–1226
you’re halfway there.”
Modifying DNA to
Eradicate Cancer
At Modifi Bio, we are changing the oncology treatment paradigm.
Bypassing the conventional approach of indirectly targeting proteins in cancer cells, Modifi Bio is redefining the rules of oncology treatment: eradicating cancer via direct DNA modification. Our novel platform demonstrates powerful anti-tumor activity in glioma and many other cancers with intrinsic DNA repair defects.
By developing therapeutics that uniquely target specific acquired cancer cell DNA mutations, we’ll improve the standard of cancer therapy and patient care. We are grateful for the support of the National Cancer Institute and our investors as we work to change how cancer will be treated in the future.
Our
Team
Modifi Bio’s team includes world-renowned scientists, clinicians and experienced biotech entrepreneurs with deep expertise in synthetic chemistry, DNA repair, and translational research in oncology.
Ranjit Bindra, MD, PhD
Harvey and Kate Cushing Professor
Yale Brain Tumor Center Co-Director
Yale Medical School
Co-Founder
Seth Herzon, PhD
Milton Harris ’29 Professor
Chemistry and Pharmacology
Yale University
Co-Founder
Kingson Lin, PhD
MD/PhD Student, Soros Fellow
Yale Medical School
Co-Founder
Kevin Rakin
Partner
HighCape Capital
Co-Founder
Joseph Park, PharmD
Vice President, Corporate Development & Clinical Affairs
Nate Fishkin, PhD
SVP, Drug Discovery and Early Development
Bruce Ruggeri, PhD
Vice President, Pharmacology
Ashish Juvekar, PhD
Director, Biology
Kyle Tarantino, PhD
Director, Chemistry
Our
Scientific Advisory Board
Michael Dillon, PhD
Senior Scientific Advisor
Former CSO, IDEAYA
Roger Stupp, MD
Chief, Neuro-Oncology
Northwestern University
Manmeet Ahluwalia, MD
Deputy Director & CSO
Miami Cancer Institute
Peter Glazer, MD, PhD
Chair, Radiation Oncology
Yale Medical School
Patricia LoRusso, DO
Associate Director for Experimental Therapeutics
Yale University
Jann Sarkaria, MD
Professor, Radiation Oncology
Mayo Clinic
Joseph Costello, PhD
Chair, Neuro-Oncology
Univ. California San Francisco
Vishwas Paralkar, PhD
Chief Scientific Officer
Cybrexa Therapeutics
Kat Kayser-Bricker, PhD
Chief Scientific Officer
Halda Therapeutics
Lucas De Breed, PhD, MBA
Director, Investments at BrightEdge
American Cancer Society
The
Science
Modifi Bio is a preclinical stage biotechnology company creating a new class of molecules, designed to be delivered orally, that aim to selectively kill cancer cells via direct cancer DNA modification. The technology bypasses conventional approaches that indirectly target proteins in cancer cells and has already demonstrated robust anti-tumor activity in cancer cells while sparing normal tissue in a laboratory study. These novel molecules fragment in cells and induce DNA modifications, which are irreparable in cancer cells with DNA repair defects.
In our recent Science publication, this new class of chameleon-like molecules was validated as exquisitely active and selective against cancer cells that lack expression of a key DNA repair protein called MGMT (O6-methylguanine methyl transferase) and can overcome key resistance mechanisms in cancer.
Approximately half of all glioblastomas and up to 80% of gliomas lack MGMT, making these cancers a natural first target for our approach. Emerging research indicates that MGMT deficiency is seen in many other tumor types, suggesting broad applicability for this strategy in treating cancer.
Modifi
Careers
Bold and innovative, we plan to disrupt conventional cancer treatment methods to achieve outcomes previously deemed impossible. Do you have a sense of adventure?
Join us—let’s redefine oncology drug discovery.